Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial

Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2015-06, Vol.26 (6), p.1254-1262
Hauptverfasser: Fontein, D.B.Y., Klinten Grand, M., Nortier, J.W.R., Seynaeve, C., Meershoek-Klein Kranenbarg, E., Dirix, L.Y., van de Velde, C.J.H., Putter, H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1262
container_issue 6
container_start_page 1254
container_title Annals of oncology
container_volume 26
creator Fontein, D.B.Y.
Klinten Grand, M.
Nortier, J.W.R.
Seynaeve, C.
Meershoek-Klein Kranenbarg, E.
Dirix, L.Y.
van de Velde, C.J.H.
Putter, H.
description Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU. Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics. A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant. The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.
doi_str_mv 10.1093/annonc/mdv146
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdv146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419318162</els_id><sourcerecordid>S0923753419318162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWwZIv8AwG_8jC7qpSHVMSmrCNnMgaj1KnstFL_HlcBdqxGmnvmanQIuebsljMt74z3vYe7TbvnqjghU54XOquY4qdkyrSQWZlLNSEXMX4xxgot9DmZiLwqhJJ6SpqHgzcbB3QbsHUwuN5T52kT0MSBgvGA4T6F_d75D2rT1jWuc8PhSEHnvAPTpdykU0C6i0ds-ES6Xs5f6RCc6S7JmTVdxKufOSPvj8v14jlbvT29LOarDGTFhsxYoUECKhStUlYUuWirUvOiFFyjtApyLkEbpiumrSlLrkvLscgrmXDeyBnJxl4IfYwBbb0NbmPCoeasPrqqR1f16CrxNyO_3TUbbP_oXzkJKEcA09d7h6GO4DAZaV1AGOq2d_9UfwP7XnuF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Fontein, D.B.Y. ; Klinten Grand, M. ; Nortier, J.W.R. ; Seynaeve, C. ; Meershoek-Klein Kranenbarg, E. ; Dirix, L.Y. ; van de Velde, C.J.H. ; Putter, H.</creator><creatorcontrib>Fontein, D.B.Y. ; Klinten Grand, M. ; Nortier, J.W.R. ; Seynaeve, C. ; Meershoek-Klein Kranenbarg, E. ; Dirix, L.Y. ; van de Velde, C.J.H. ; Putter, H.</creatorcontrib><description>Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU. Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics. A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant. The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdv146</identifier><identifier>PMID: 25862439</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Belgium ; Biomarkers, Tumor - analysis ; breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Chemotherapy, Adjuvant ; Decision Support Techniques ; dynamic prediction ; Feasibility Studies ; Female ; Humans ; landmark analysis ; Mastectomy - adverse effects ; Mastectomy - mortality ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Netherlands ; Nomograms ; Patient Selection ; personalized therapy ; Predictive Value of Tests ; Receptor, ErbB-2 - analysis ; Risk Assessment ; Risk Factors ; Survival Analysis ; survival probability ; Time Factors ; Treatment Outcome</subject><ispartof>Annals of oncology, 2015-06, Vol.26 (6), p.1254-1262</ispartof><rights>2015 European Society for Medical Oncology</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</citedby><cites>FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25862439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fontein, D.B.Y.</creatorcontrib><creatorcontrib>Klinten Grand, M.</creatorcontrib><creatorcontrib>Nortier, J.W.R.</creatorcontrib><creatorcontrib>Seynaeve, C.</creatorcontrib><creatorcontrib>Meershoek-Klein Kranenbarg, E.</creatorcontrib><creatorcontrib>Dirix, L.Y.</creatorcontrib><creatorcontrib>van de Velde, C.J.H.</creatorcontrib><creatorcontrib>Putter, H.</creatorcontrib><title>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU. Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics. A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant. The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Belgium</subject><subject>Biomarkers, Tumor - analysis</subject><subject>breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Decision Support Techniques</subject><subject>dynamic prediction</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Humans</subject><subject>landmark analysis</subject><subject>Mastectomy - adverse effects</subject><subject>Mastectomy - mortality</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Netherlands</subject><subject>Nomograms</subject><subject>Patient Selection</subject><subject>personalized therapy</subject><subject>Predictive Value of Tests</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>survival probability</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWwZIv8AwG_8jC7qpSHVMSmrCNnMgaj1KnstFL_HlcBdqxGmnvmanQIuebsljMt74z3vYe7TbvnqjghU54XOquY4qdkyrSQWZlLNSEXMX4xxgot9DmZiLwqhJJ6SpqHgzcbB3QbsHUwuN5T52kT0MSBgvGA4T6F_d75D2rT1jWuc8PhSEHnvAPTpdykU0C6i0ds-ES6Xs5f6RCc6S7JmTVdxKufOSPvj8v14jlbvT29LOarDGTFhsxYoUECKhStUlYUuWirUvOiFFyjtApyLkEbpiumrSlLrkvLscgrmXDeyBnJxl4IfYwBbb0NbmPCoeasPrqqR1f16CrxNyO_3TUbbP_oXzkJKEcA09d7h6GO4DAZaV1AGOq2d_9UfwP7XnuF</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Fontein, D.B.Y.</creator><creator>Klinten Grand, M.</creator><creator>Nortier, J.W.R.</creator><creator>Seynaeve, C.</creator><creator>Meershoek-Klein Kranenbarg, E.</creator><creator>Dirix, L.Y.</creator><creator>van de Velde, C.J.H.</creator><creator>Putter, H.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201506</creationdate><title>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</title><author>Fontein, D.B.Y. ; Klinten Grand, M. ; Nortier, J.W.R. ; Seynaeve, C. ; Meershoek-Klein Kranenbarg, E. ; Dirix, L.Y. ; van de Velde, C.J.H. ; Putter, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-af29c3ce4e2d44f2652d879167219e3f4c513c9a09809fa77197f1e658344f1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Belgium</topic><topic>Biomarkers, Tumor - analysis</topic><topic>breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Decision Support Techniques</topic><topic>dynamic prediction</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Humans</topic><topic>landmark analysis</topic><topic>Mastectomy - adverse effects</topic><topic>Mastectomy - mortality</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Netherlands</topic><topic>Nomograms</topic><topic>Patient Selection</topic><topic>personalized therapy</topic><topic>Predictive Value of Tests</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>survival probability</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fontein, D.B.Y.</creatorcontrib><creatorcontrib>Klinten Grand, M.</creatorcontrib><creatorcontrib>Nortier, J.W.R.</creatorcontrib><creatorcontrib>Seynaeve, C.</creatorcontrib><creatorcontrib>Meershoek-Klein Kranenbarg, E.</creatorcontrib><creatorcontrib>Dirix, L.Y.</creatorcontrib><creatorcontrib>van de Velde, C.J.H.</creatorcontrib><creatorcontrib>Putter, H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fontein, D.B.Y.</au><au>Klinten Grand, M.</au><au>Nortier, J.W.R.</au><au>Seynaeve, C.</au><au>Meershoek-Klein Kranenbarg, E.</au><au>Dirix, L.Y.</au><au>van de Velde, C.J.H.</au><au>Putter, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2015-06</date><risdate>2015</risdate><volume>26</volume><issue>6</issue><spage>1254</spage><epage>1262</epage><pages>1254-1262</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experience events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP) during FU. Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a proportional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status, T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was designed to calculate 5-year DOS based on individual characteristics. A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity were HR = (8.427 × 0.583tP, HR = (3.621 × 0.816tP, and HR = (1.235 × 0.851tP, respectively. Treatment discontinuation was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covariates were time-constant. The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and optimizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomogram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an independent dataset is still needed.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25862439</pmid><doi>10.1093/annonc/mdv146</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2015-06, Vol.26 (6), p.1254-1262
issn 0923-7534
1569-8041
language eng
recordid cdi_crossref_primary_10_1093_annonc_mdv146
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Belgium
Biomarkers, Tumor - analysis
breast cancer
Breast Neoplasms - chemistry
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Chemotherapy, Adjuvant
Decision Support Techniques
dynamic prediction
Feasibility Studies
Female
Humans
landmark analysis
Mastectomy - adverse effects
Mastectomy - mortality
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Netherlands
Nomograms
Patient Selection
personalized therapy
Predictive Value of Tests
Receptor, ErbB-2 - analysis
Risk Assessment
Risk Factors
Survival Analysis
survival probability
Time Factors
Treatment Outcome
title Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T01%3A03%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamic%20prediction%20in%20breast%20cancer:%20proving%20feasibility%20in%20clinical%20practice%20using%20the%20TEAM%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Fontein,%20D.B.Y.&rft.date=2015-06&rft.volume=26&rft.issue=6&rft.spage=1254&rft.epage=1262&rft.pages=1254-1262&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdv146&rft_dat=%3Celsevier_cross%3ES0923753419318162%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25862439&rft_els_id=S0923753419318162&rfr_iscdi=true